SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-034773
Filing Date
2022-10-20
Accepted
2022-10-20 17:15:39
Documents
12
Period of Report
2022-10-20
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20221020.htm   iXBRL 8-K 36311
  Complete submission text file 0001564590-22-034773.txt   164221

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA abio-20221020.xsd EX-101.SCH 5609
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20221020_lab.xml EX-101.LAB 19329
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20221020_pre.xml EX-101.PRE 11501
6 EXTRACTED XBRL INSTANCE DOCUMENT abio-8k_20221020_htm.xml XML 3519
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 221321697
SIC: 2835 In Vitro & In Vivo Diagnostic Substances